New Review of the Real-world Data on the Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors - touchENDOCRINOLOGY
LONDON, May 24, 2018 /PRNewswire/ --
Baptist Gallwitz; European Endocrinology. 2018;14(1):17-23 DOI: https://doi.org/10.17925/EE.2018.14.1.17
(Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )
Published recently in European Endocrinology, the peer-reviewed, PubMed-indexed journal from touchENDOCRINOLOGY, Baptist Gallwitz discusses the recently published real-world data on the cardiovascular (CV) benefits associates with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D). T2D is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions. In a recent cardiovascular outcomes trial, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), the sodium-glucose SGLT2 inhibitor empagliflozin was shown to reduce CV mortality and heart failure in high-risk patients with T2D with a previous CV event or with established CV disease (CVD). Recently published data from the Canagliflozin Cardiovascular Assessment Study (CANVAS-PROGRAM) study suggested that the cardiovascular benefits of empagliflozin are also seen with the SGLT2-inhibitor canagliflozin, indicating a class effect of SGLT2 inhibitors. Evidence for a class effect has also been shown by meta-analyses and real-world studies, including the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) and The Health Improvement Network (THIN) databases. These findings also suggest the results of EMPA-REG OUTCOME can be applied to patients with T2D with a broader CV risk profile, including people at low risk of CVD.
The full peer-reviewed, open-access article is available here:
https://doi.org/10.17925/EE.2018.14.1.17
Disclosure: Baptist Gallwitz discloses the following: Board Member/Advisory Panel for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Janssen, Merck Sharp & Dohme, Mylan, Novartis, Novo Nordisk. Speaker honoraria: Amgen, Abbott, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novo Nordisk, Sanofi. The publication of this article was supported by AstraZeneca. The views and opinions expressed are those of the author and do not necessarily reflect those of AstraZeneca.
touchENDOCRINOLOGY (a division of Touch Medical Media) publishesEuropean Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142.
For inquires please contact:
Nicola Cartridge - Editorial Director
[email protected]
+44-(0)-207-193-3186
Leading the Debate on the Advances in Healthcare
SOURCE touchENDOCRINOLOGY
Share this article